Cochrane · systematic review · CD000029
Oral antiplatelet therapy for acute ischaemic stroke
Minhas, JS, Chithiramohan, T, Wang, X, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
StrokeAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 2 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antiplatelet drug compared to control in acute presumed ischaemic stroke for acute ischaemic stroke
Population: acute ischaemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death or dependence at end of Antiplatelet drug vs control | Peto OR 0.95 [0.91, 0.99] | 7 studies · 42034 participants | Moderate |
Death from any cause during Antiplatelet drug vs control | Peto OR 0.93 [0.87, 0.98] | 10 studies · 41929 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Pulmonary embolism during treatment period Antiplatelet drug vs control | Peto OR 0.71 [0.53, 0.96] | 7 studies · 41042 participants | Very low Downgraded: risk of bias, imprecision |
Recurrent ischaemic/unknown stroke during treatment period Antiplatelet drug vs control | Peto OR 0.79 [0.7, 0.88] | 9 studies · 41652 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Symptomatic intracranial haemorrhage during treatment period Antiplatelet drug vs control | Peto OR 1.18 [0.97, 1.44] | 9 studies · 41652 participants | Very low Downgraded: risk of bias, imprecision |
Major extracranial haemorrhage during treatment period Antiplatelet drug vs control | Peto OR 1.69 [1.35, 2.11] | 7 studies · 41042 participants | Very low Downgraded: risk of bias, imprecision |
Complete recovery from stroke (post hoc) Antiplatelet drug vs control | Peto OR 1.06 [1.01, 1.11] | 2 studies · 40541 participants | Moderate |